PSR Orphan Experts

Ergomed to acquire CRO PSR Group for €5.7M

Tuesday, October 3, 2017

Ergomed, a specialized pharmaceutical services and drug development company, announced the proposed acquisition of PSR Group, an international niche CRO specialized in orphan drug development. Ergomed has agreed to acquire 100% of the issued share capital of PSR Group for a total consideration of up to €5.7 million.

[Read More]

PSR Orphan Experts launches patient organization advisory board

Wednesday, November 9, 2016

PSR Orphan Experts, a specialty orphan drug consulting and clinical research company, has announced the launch of a new Patient Organization Advisory Board to bolster its regulatory and clinical-stage drug development services in rare diseases. The advisory board comprises of up to seven experts from patient organizations, representing a wide range of therapeutic areas, and will play a key role in driving successful orphan drug programs for PSR’s clients.

[Read More]

Agility Clinical partners with PSR Orphan Experts

Wednesday, March 6, 2013

Carlsbad, Calif.-based Agility Clinical, a specialty CRO, has partnered with PSR Orphan Experts, a specialty consulting and clinical research company based in the Netherlands., a move that will provide clients with access to orphan drug development expertise and services on both sides of the Atlantic. The term “orphan drug” refers to pharmaceutical products developed specifically to treat rare diseases that affect fewer than 200,000 Americans or less than one in 2,000 Europeans.

[Read More]